| Market Capitalization (Millions $) |
1,831 |
| Shares
Outstanding (Millions) |
76 |
| Employees |
260 |
| Revenues (TTM) (Millions $) |
105 |
| Net Income (TTM) (Millions $) |
-163 |
| Cash Flow (TTM) (Millions $) |
-30 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Xencor Inc is a biopharmaceutical company that uses its proprietary XmAb technology platform to develop and commercialize novel antibody therapeutics. The company's mission is to improve patient outcomes and quality of life by developing innovative and differentiated therapeutics.
Xencor's XmAb technology platform is a versatile antibody engineering technology that enhances the efficacy and safety of antibodies. It can be used to improve the half-life of antibodies, increase their potency, and reduce their immunogenicity. The XmAb technology platform has been applied to the development of several antibody candidates in various therapeutic areas including oncology, autoimmune diseases, and allergic diseases.
One of the key strengths of Xencor is its collaboration strategy. The company has partnered with several pharmaceutical and biotechnology companies including Novartis, Alexion Pharmaceuticals, and MorphoSys to develop and commercialize XmAb-based therapeutics. Xencor has also entered into research collaborations with academic institutions and government agencies.
Xencor has a diverse pipeline with several candidates in different stages of clinical development. The company's lead candidate, XmAb5871, is a first-in-class monoclonal antibody that targets the FceRIIb receptor on B cells. It is being developed for the treatment of autoimmune diseases including systemic lupus erythematosus and IgG4-related disease. XmAb7195 is another candidate being developed in collaboration with Novartis for the treatment of acute myeloid leukemia and other hematologic malignancies.
In addition to its pipeline of candidates, Xencor also has a robust technology portfolio. The company has developed several proprietary technologies including Xtende Fc technology, which extends the half-life of antibodies, and bispecific Fc technology that enables the creation of bispecific antibodies with improved therapeutic properties.
Overall, Xencor is a leading biopharmaceutical company with a promising pipeline of candidates and innovative technology platform. The company's collaborations, proprietary technologies, and diverse pipeline positions it to continue to deliver value to patients and shareholders in the years to come.
Company Address: 465 North Halstead Street Pasadena 91107 CA
Company Phone Number: 305-5900 Stock Exchange / Ticker: NASDAQ XNCR
|
0.2 %